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Abstract: Malignant melanoma is a highly lethal disease unless detected early. Single-agent 
chemotherapy is well tolerated but is associated with very low response rates. Combination 
chemotherapy and biochemotherapy may improve objective response rates but do not prolong 
survival and are associated with greater toxicity. Immunotherapeutic approaches such as high-
dose interleukin-2 are associated with durable responses in a small percentage of patients, but 
are impractical for many patients due to accessibility and toxicity issues. Elucidations of the 
molecular mechanisms of carcinogenesis in melanoma have expanded the horizon of opportunity 
to alter the natural history of the disease. Multiple signal transduction pathways seem to be 
aberrant and drugs that target them have been and continue to be in development. In this review 
we present data on the most promising targeted agents in development, including B-raf inhibi-
tors and other signal transduction inhibitors, oligonucleotides, proteasome inhibitors, as well 
as inhibitors of angiogenesis. Most agents are in early phase trials although some have already 
reached phase III evaluation. As knowledge and experience with targeted therapy advance, 
new challenges appear to be arising particularly in terms of resistance and appropriate patient 
selection.
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Introduction
Malignant melanoma is the most rapidly increasing cancer in incidence in the United 
States with an estimated 62,480 new cases diagnosed in 2008. In its early stages, 
melanoma can be surgically cured, leading to five-year survival rates exceeding 90%. 
However, metastatic disease is uniformly fatal with five-year survival rates less than 2%. 
Its public health impact is best illustrated in the fact that 50% of patients dying of 
melanoma would have lived another 25 years. While adjuvant therapy with high-dose 
interferon alpha-2b (INFα-2b) can decrease the risk of recurrence and improve survival 
in a subset of patients in the adjuvant setting, no available therapy has made any impact 
on improving survival in the metastatic setting. Dacarbazine (DTIC) remains the only 
approved chemotherapeutic agent despite modest response rates that do not exceed 10%. 
Multiple other chemotherapeutic agents, used singly or in combination, have failed 
to improve on the results obtained with DTIC. Only high-dose interleukin-2 (IL-2) 
has received US Food and Drug Administration (FDA)-approval based mostly on the 
achievement of durable responses in 5% of patients; however IL-2 remains restricted 
for a select group of patients that can withstand its toxicities and can only be delivered 
in specialized settings. There is an urgent need for new agents that can alter the natural 
history of melanoma and improve response rates and survival.
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The era of targeted therapies, which was heralded by 
a better understanding of tumor biology, offers significant 
promise in the treatment of melanoma but also presents 
new challenges. In this review, the most prominent targeted 
agents investigated in melanoma therapy will be presented 
with emphasis on future directions in which patient selection 
and combination therapy will likely become standard.
Sorafenib
Mechanism of action
Sorafenib is FDA-approved for the treatment of advanced 
primary renal cell carcinoma and advanced primary 
hepatocellular carcinoma. It is an oral multikinase inhibitor 
that inhibits tumor growth by acting on the tumor cells 
and cells of the tumor vasculature. It inhibits tumor cell 
proliferation by targeting the mitogen-activated protein kinase 
(MAPK) pathway at the level of Raf kinase and/or induces 
tumor cell apoptosis. Sorafenib also potently inhibits vascular 
endothelial growth factor receptor (VEGFR)-1, -2 and -3, and 
platelet-derived growth factor receptor (PDGFR)-β tyrosine 
kinase autophosphorylation. These proangiogenic receptor 
tyrosine kinases (RTKs) signal through Raf/MEK/ERK to 
induce proliferation and prolong the survival of vascular 
endothelial cells, which form new blood vessels. The proan-
giogenic RTKs also promote the proliferation, survival, and 
recruitment of pericytes, by signaling through Raf, resulting 
in the stabilization of newly formed blood vessels.1
BRAF is an activating oncogenic mutation found in 60% 
of melanomas.V600E is the most prevalent mutation in 
BRAF. Most of the transforming activity of the BRAF V600E 
occurs through the activation of the MAPK pathway.2 Somatic 
V600E mutated BRAF showed an increased sensitivity 
to (MEK) inhibition and resulted in more potent tumor 
cell growth arrest than those cell lines not expressing the 
V600E mutation. Regardless of BRAF V600E mutational 
status, virtually all melanomas have activity in the MAPK 
pathway.3
Sorafenib’s multiple targets, including Raf-1,4,5 wild-type 
BRAF, oncogenic b-raf V600E, and proangiogenic RTKs,6 
enable its action on tumor cells as well as on tumor 
vasculature to induce apoptosis and inhibit proliferation 
as well as angiogenesis in preclinical models.7–9 This 
provides sorafenib with the potential for activity against a 
wide variety of tumor types. The targeting of multiple Raf 
isoforms and RTKs by sorafenib may also provide a means to 
overcome multidrug resistance. Expression of the multidrug 
resistance 1 (mdr-1) gene is associated with solid tumors that 
have a high level of intrinsic or acquired chemoresistance.10 
In addition, downregulation of antiapoptotic molecules may 
help sensitize tumor cells to chemotherapy. The inhibition 
of tumor angiogenesis can therefore enhance delivery of 
cytotoxic agents by affecting the vasculature, and increase the 
effectiveness of concomitantly administered chemotherapy.
Safety profile
Single-agent sorafenib at 400 mg twice daily (bid) was found 
to be generally well tolerated in phase I–III clinical trials. 
The majority of adverse events were mild to moderate in 
severity, followed a predictable course, and were manageable. 
The most frequently reported drug-related adverse events 
were dermatologic (hand–foot skin reaction [HFSR], rash/
desquamation, gastrointestinal [diarrhea], and constitutional 
[fatigue]).11–13 Severe biochemical abnormalities, myelosup-
pression, hematologic, cardiovascular, hepatic, and renal 
toxicities were rarely reported.12 Interestingly, treatment-
emergent hypertension was observed in 5%–17% (5% at 
Grade 3 or 4) of patients receiving sorafenib 400 mg bid 
and was readily manageable with antihypertensives.11,12
The favorable safety profile of sorafenib on a continuous 
administration schedule and its convenient oral route of 
administration suggests that it could be combined with 
other antitumor agents, including cytotoxic agents that are 
usually associated with higher levels of toxicity, as well as 
other targeted therapies.14
Clinical experience in melanoma
The effects of the combination of paclitaxel, carboplatin, 
and sorafenib have been investigated in a phase I/II trial of 
35 patients with progressive stage IV melanoma pretreated 
with no more than three previous chemotherapy regimens. 
The preliminary results showed a high rate of partial response 
(PR) 40% and stable disease (SD) 43%, but the antitu-
mor activity was independent of b-raf mutational status. 
Responses were observed mainly in patients with skin, 
subcutaneous, and lymph node metastases (stage M1a) and 
a limited number of previous therapies. This has lead to two 
large multicenter randomized placebo-controlled phase III 
trials investigating the addition of sorafenib to a carboplatin 
and paclitaxel backbone in both first- and second-line therapy 
of metastatic melanoma. Both trials have been concluded 
although results from the first-line trial have not been 
released yet. The PRISM trial was a phase III, randomized, 
double-blind, placebo-controlled study conducted to evaluate 
the efficacy and safety of sorafenib with carboplatin and 
paclitaxel (CP) in patients with advanced melanoma who had 
progressed on a DTIC or temozolomide (TMZ)-containing 
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regimen (second line setting). A total of 270 patients were 
randomly assigned to each arm. The median progression-free 
survival (PFS) was 17.9 weeks for the placebo plus CP arm 
and 17.4 weeks for the sorafenib plus CP arm (hazard ratio, 
0.91; 99% confidence interval [CI]: 0.63 to 1.31; two-sided 
log-rank test, P  0.49). Response rate was 11% with placebo 
versus 12% with sorafenib. The addition of sorafenib to 
CP did not improve any of the end points over placebo plus 
CP and cannot be recommended in the second-line setting 
for patients with advanced melanoma. Both regimens had 
clinically acceptable toxicity profiles with no unexpected 
adverse events.15
Sorafenib was also evaluated in combination with DTIC 
in a single-center, open-label, phase I, dose-escalation trial 
in patients with metastatic melanoma.16 Among 18 evaluable 
patients, three (17%) had PR and 11 (61%) had SD. This 
combination was further evaluated in clinical trials, including 
a phase II open-label, first-line, uncontrolled study as well as 
a phase II randomized, placebo-controlled study in patients 
with unresectable stage III or IV melanoma. In the uncon-
trolled phase II study, sorafenib and DTIC were well tolerated 
and yielded promising efficacy results in these patients with 
a poor prognosis. Eight patients (10%) achieved PR and 
34 (41%) had SD; the median PFS duration was 14 weeks 
and the median overall survival (OS) time was 41 weeks.17 
These data are encouraging, compared with DTIC alone, 
which achieved a response rate of 7.5% and a PFS time of 
six weeks. Results from a placebo-controlled study support 
a better efficacy trend in terms of objective responses and 
PFS compared with DTIC alone in advanced melanoma. 
The median PFS times were 21.1 versus 11.7 weeks for 
sorafenib in combination with DTIC compared with DTIC 
plus placebo, respectively.18
Sorafenib has been evaluated in combination with TMZ, 
an oral alkylating agent approved for the treatment of patients 
with metastatic melanoma with or without brain metastases. 
Results from a four-arm phase II trial demonstrated encour-
aging antitumor activity and tolerability of this combination 
in patients with metastatic melanoma. An overall response 
rate of 19% was observed in 78 patients across two arms of 
the study.19
Overall, the most promising sorafenib-based combination 
approach appears to involve DTIC, which produced a fairly 
consistent level of preliminary responses or SD in patients 
with advanced melanoma.17,18,20
While the development of sorafenib has been fraught 
with difficulties, in some respects related to selectivity, novel 
BRAF kinase inhibitors that are selective for the oncogenic 
V600E mutant are showing exciting results. A phase I trial 
of PLX4032, an oral, selective inhibitor of the V600E mutant 
BRAF enrolled 54 patients, most with metastatic melanoma. 
A change in formulation was to improve bioavailability after 
around half the patients were enrolled and the maximum 
tolerated dose of the new formulation was determined to 
be 720 mg bid. Of the melanoma patients, five of the seven 
with BRAF  V600E treated at 240 mg bid had tumor regres-
sion, with one confirmed PR and one unconfirmed PR; two 
of four patients with unknown V600E status had tumor 
regression one reaching a PR; two BRAF wild-type patients 
had progressive disease. Three thyroid cancer patients with 
V600E mutations had tumor regression (range 9%–16%) 
that did not reach PR. The main dose-limiting toxicities 
included rash, fatigue, elevated liver enzymes, and pancyto-
penia. PLX4032 appears to be a very promising novel and 
specific mutant BRAF kinase inhibitor that may pave the way 
for more effective targeted agents.21
Oblimersen
Mechanism of action
Oblimersen (OBL) is a Bcl-2 antisense oligonucleotide that 
selectively targets Bcl-2 RNA for degradation by RNase 
H thereby decreasing Bcl-2 protein production. The Bcl-2 
protein, which is a potent inhibitor of apoptosis, is overex-
pressed in many cancers, including follicular lymphomas, 
breast, colon and prostate cancers, and intermediate-/high-
grade lymphomas. By reducing the amount of Bcl-2 protein 
in cancer cells, OBL may enhance the effectiveness of 
conventional anticancer treatments.22
Clinical experience in melanoma
In a phase I/IIa trial in which OBL was administered twice 
daily by subcutaneous injection to patients with metastatic 
melanoma, patients also received DTIC on day 5 of each 
week. Six of 14 evaluable patients (43%) experienced 
antitumor responses, including a pathologically confirmed 
response in an elderly patient. Two additional patients 
had SD. The median survival duration had exceeded one year 
by the time the study was reported. In 10/12 (83%) evaluable 
patients, OBL treatment caused the downregulation of Bcl-2 
protein, with the maximum response occurring at day 5 of 
treatment.23
Similarly, in a dose-escalating study of an infusion 
regimen of OBL in combination with DTIC in 14 patients 
with stage IV metastatic melanoma, most patients had reduc-
tions from baseline in Bcl-2 protein levels in cutaneous 
melanoma metastases. Antitumor activity was observed 
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in six patients, including one complete response, two 
PR and two minor responses with SD for 1 year. The 
estimated median survival duration at the time of the report 
was 1 year. Patients received a 14-day continuous intravenous 
infusion of OBL 0.6–6.5 mg/kg/day plus intravenous DTIC 
200 mg/m2/day on days 5–9 of OBL administration. Treatment 
cycles could be repeated at 28-day intervals in patients who 
were stable or who experienced a response.24
An OBL–TMZ–albumin-bound paclitaxel (ABX) 
combination was synergistic in the preclinical setting, and a 
phase I/II study of this combination was initiated in patients 
with metastatic melanoma and normal lactate dehydrogenase 
(LDH). TMZ is an orally administered chemotherapy with 
a mechanism of action and efficacy in melanoma similar to 
that of DTIC. ABX is currently being explored in melanoma. 
Chemotherapy-naïve patients with advanced melanoma, 
baseline LDH  1.1 × upper limit of normal (ULN), and 
measurable disease were enrolled in the study. Treatment 
included OBL 7 mg/kg/d (continuous intravenous infusion, 
days 1–7 and 22–29), TMZ 75 mg/m2/d (days 1–42), and 
ABX 175 mg/m2 (days 7 and 29) in cohort 1 and 260 mg/m2 
in cohort 2 for four 56-day cycles. All 14 (1-M1a, 5-M1b, 
8-M1c) patients planned for cohort 1 have been enrolled; 
treatment is ongoing in 10. Four patients have achieved a 
PR (50% tumor reduction) lasting more than two cycles 
(range: 3–6 cycles); two with SD lasting three cycles; and 
two with PD after one cycle. In six patients it is too early 
to assess response. OBL and TMZ have no effect on ABX 
pharmacokinetics. Tumor and serologic assessment of 
biomarkers correlate with clinical and radiologic responses 
or progression. Prolonged clinical activity has been seen 
and the regimen is safe and well tolerated. Cohort 2 is open 
to enrolment.25
A phase III study (NCT00016263) of OBL in combina-
tion with DTIC was conducted in patients with malignant 
melanoma. Patients were randomly assigned to receive DTIC 
alone or in combination with OBL. The addition of OBL 
to DTIC improved median overall survival, compared with 
that in patients treated with DTIC alone (9.0 vs 7.8 months); 
however, the difference between the groups was not significant 
(P = 0.077). In addition, the analyses indicated that a blood 
test (LDH) could be used to identify patients who were likely 
to derive the most benefit from OBL therapy. Baseline LDH 
was highly predictive of OBL effect in melanoma indepen-
dently of tumor burden; this suggested that elevated LDH may 
reflect aggressive tumor biology. After a minimum follow-
up duration of 24 months, patients treated with OBL plus 
DTIC versus DTIC alone yielded significantly higher overall 
response rates (13.5% vs 7.5%, P = 0.007), complete responses 
(2.8% vs 0.8%, P = 0.03), durable responses (7.3% vs 3.6%, 
P = 0.03) and median PFS (2.6 vs 1.6 months, P = 0.0007).26 
In summary, the use of OBL with DTIC can improve multiple 
outcomes in patients with advanced melanoma particularly 
those with normal base line LDH.
The most common side effects of OBL include nausea, 
vomiting, pyrexia, fatigue, anorexia, thrombocytopenia, 
neutropenia, and anemia. OBL-associated thrombocytopenia 
did not cause an increase in serious bleeding, and the 
incidence of neutropenic fever was low.26
Bevacizumab
Mechanism of action
Bevacizumab is FDA-approved for use in metastatic 
colorectal cancer, non-small cell lung cancer, and metastatic 
breast cancer. It is a recombinant, humanized Ab targeted 
against VEGF-A and blocks its binding to the VEGF 
receptors. VEGF regulates vascular proliferation and 
induces permeability, both of which are important for 
tumor growth. It also has antiapoptotic activities in newly 
formed endothelial cells. The expression of VEGF in 
tumor cells is stimulated by hypoxia, hypoglycemia, Ras 
antigen, and inactivation of tumor suppressor gene p53/von 
Hippel–Landau gene. Melanoma cells with a nonaggressive 
phenotype when exposed to chemotherapy acquire a much 
more tumorigenic and metastatic phenotype.27 This is in 
part through overproduction of VEGF, which may render 
both endothelial and cancer cells resistant to chemotherapy 
through a variety of mechanisms: 1) enhancement of tumor 
growth through induction of angiogenesis; 2) impairment of 
delivery of chemotherapy to the tumor through increase in 
interstitial fluid pressure;28 3) protection of tumor-associated 
endothelial cells against cytotoxicity;29 and 4) initiation of 
autocrine survival signals in cancer cells.30,31 In comparison 
with conventional chemotherapy, the antiangiogenic effects 
of bevacizumab are indirect and not necessarily lethal.32 
However, the addition of bevacizumab to conventional 
chemotherapy has been shown to control tumor growth and 
progression more effectively than chemotherapy alone in 
patients with certain solid tumors.33,34 This probable expla-
nation lies in bevacizumab’s ability to dampen the effects of 
VEGF upregulation induced by chemotherapy.
Safety profile
The most common adverse events for bevacizumab were 
neutropenia, anemia, thrombocytopenia, fatigue, nausea/
vomiting, neuropathy, hypertension, bleeding episodes, 
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thrombotic events, and proteinuria ranging in severity from 
clinically silent to nephritic syndrome. Further studies are 
required to determine the relative value of bevacizumab in 
combination with chemotherapy.35
Clinical experience in melanoma
A randomized phase II trial of bevacizumab with or without 
daily low-dose INFα-2b in metastatic malignant melanoma. 
Patients exhibiting a clinical response or stable disease after 
12 weeks were treated until disease progression. Thirty-two 
patients (16 per arm) were accrued. Eight patients (five beva-
cizumab, three bevacizumab plus INFα-2b) had prolonged 
disease stabilization (24 to 146 weeks). Plasma levels of 
VEGF and fibroblast growth factor (FGF) did not correlate 
with any clinical parameter. The patient with the longest 
period of stable disease had the highest baseline VEGF and 
FGF. Bevacizumab was well tolerated and prolonged disease 
stabilization was achieved in one-quarter of metastatic 
melanoma patients. Low-dose IFNα-2b did not augment the 
activity of bevacizumab.32
A two-stage phase II clinical trial was conducted in 
patients with unresectable stage IV metastatic melanoma to 
assess antitumor activity and the toxicity profile of the com-
bination of carboplatin, paclitaxel (80 mg/m2 intravenous on 
days 1, 8, and 15), and bevacizumab (10 mg/kg intravenous 
on days 1 and 15). Treatment was continued until progres-
sion or intolerable toxicity. Fifty-three patients (62.3% male) 
were enrolled. Nine (17%) patients achieved PR, and another 
30 (57%) achieved SD for at least eight weeks. Median PFS 
and median OS were 6 and 12 months, respectively. This 
combination of carboplatin, paclitaxel, and bevacizumab 
appears to be moderately well tolerated and clinically 
beneficial in patients with metastatic melanoma.35
mTOR inhibitors
Mechanism of action
Rapamycin (sirolimus) is an immunosuppressive drug 
with antiproliferative activity. CCI-779 is an ester analog 
of rapamycin with improved aqueous solubility and 
pharmacokinetic properties (432917). Drugs of this class 
inhibit cell cycle progression by binding to FK506-binding 
protein-12 (FKBP12) to form a complex that interacts with 
the “mammalian target of rapamycin” (mTOR), resulting 
in inhibition of signal transduction pathways required for 
progression through the cell cycle.36 Inhibition of mTOR 
suppresses p70 s6k activity, decreasing translation of elements 
of the translational machinery. Inhibition of mTOR by 
rapamycin/CCI-779 also prevents cyclin-dependent kinase 
activation, inhibits phosphorylation of retinoblastoma protein 
as well as accelerates the turnover of cyclin D1 that leads to a 
deficiency of active cdk4/cyclin D1 complexes, all of which can 
inhibit cell cycle kinetics at the G1/S phase transition (439022), 
(439028). Perturbation of these pathways, downstream of 
protein kinase B (PKB/AKT)/phosphoinositol-3-kinase 
(PI3K) activities, results from upstream mutations, that are 
mutated in human cancers, most commonly loss of the PTEN 
(phosphatase and tensin homolog deleted on chromosome 
10) tumor suppressor, which leads to overexpression of AKT 
or PI3K resulting in mTOR overexpression. PTEN mutations 
are found in approximately one-half of melanomas.37 The 
resulting increase in the activity of mTOR is believed to 
“uncouple” it from the normal control exerted on its activity by 
the availability of nutrients required for cell proliferation.38
Elucidation of the therapeutic mechanisms of antitumor 
activity for CCI-779 and other mTOR inhibitors has led to 
an increased understanding of the mechanisms of resistance, 
which include mutations in mTOR, FKBP12, or any of the 
many others associated with mTOR-related pathways.39
Safety profile
The dose-limiting toxicities for CCI-779 included myelo-
suppression, diarrhea, stomatitis, fever, fatigue, and hyper-
lipidemia. Skin reactions were common, ranging from dry 
desquamation to eczematoid, urticarial, and acneiform 
rash. Acute infusion reactions resembled histamine-release 
phenomena and have been avoided by premedication with 
antihistamines.40,41 Based on these safety data as well as 
pharmacokinetic and pharmacodynamic results, a fixed dose 
of 250 mg was proposed for evaluation on a weekly dosing 
schedule in patients with advanced melanoma. The spectrum 
of toxicities associated with this agent overlaps with those of 
several other drugs in routine use, which limits the choices of 
combinations that could be safely considered. The optimal use 
of this class of agents in malignancy will await the design of 
regimens that take into account the need for nonoverlapping 
clinical toxicities and complementary antitumor mechanisms 
that minimize the emergence of resistant clones.
Clinical experience in melanoma
The results of phase I trial on CCI-779 did not have 
sufficient antitumor activity in melanoma to warrant further 
evaluation as a single agent. A preliminary report in 2003 
details the results of a phase I dose-escalation study that 
combined CCI-779 with IFN-α at a low dose, which could 
be escalated in the individual patient if no dose-limiting 
toxicity of CCI-779 occurred. The authors concluded that the 
Biologics: Targets & Therapy 2009:3480
Tawbi and Nimmagadda Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
combination was well tolerated and potentially active, with 
mechanisms of action that included both direct antitumor 
activity and antiangiogenic effects.42
Bortezomib
Mechanism of action
Bortezomib (PS-341) is a dipeptidyl boronic acid analog, 
which is a potent and reversible proteasome inhibitor. 
Cells exposed to PS-341 accumulate in the G2-M phase 
of the cell cycle, and some undergo apoptosis.43,44 The 
ubiquitin-mediated proteasome pathway regulates a group 
of intracellular proteins that govern cell cycle, tumor 
growth, and survival. This pathway is the principal mecha-
nism of degradation for short-lived cellular regulatory 
proteins, including p53,45 cyclins and the cyclin-dependent 
kinase inhibitors p2146 and p27, the estrogen receptor47 
and the inhibitor (IKB) of nuclear transcription factor 
kappa B (NFκB).48 NFκB mediates the transcription of 
proteins including VEGF and the cell adhesion molecules 
(CAM) E-selectin, intracellular cell adhesion molecule-1 
(ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1), 
implicated in angiogenesis and tumor metastasis in vivo, 
and regulates the inhibition of tumor necrosis factor–alpha 
(TNF-α)-mediated cell death.49 Altered degradation of 
cell cycle control proteins can result in accelerated and 
uncontrolled cell division and thereby promote cancer 
growth and spread. Central to the pathway is the 26S protea-
some, an adenosine triphosphate-dependent, multicatalytic 
protease that selectively degrades polyubiquitinated pro-
teins. Normal activity of the 26S proteasome rapidly clears 
polyubiquitinated proteins from the cell. While its inhibition 
permits accumulation of substrate polyubiquitinated proteins 
and the disruption of cell cycle checkpoints and apoptosis 
pathways, and thus offers a promising approach for the treat-
ment of malignancies. Preclinical data point to the role of 
PS-341-induced chemosensitization and radiosensitization.50
Safety profile
PS-341 can be safely administered as an intravenous bolus 
without premedication, and is generally very well tolerated. 
The major toxicities were constipation, ileus, sensory 
neuropathy, thrombocytopenia, fatigue, abdominal pain, 
infection without neutropenia and malaise. Caution should be 
exercised with PS-341 in patients with pre-existing peripheral 
neuropathy.51
With its unique mechanism of action and the lack 
of significant myelosuppression, one can anticipate an 
eventual role in cancer treatment for PS-341 and newer 
proteasome inhibitors. The rationale for drug combinations 
with nonneurotoxic drugs has been advanced and such 
trials are ongoing in phase I and phase II studies. It is also 
possible that potentially neurotoxic drugs might be safely 
combined with PS-341 without undue problems if the 
dose of these agents is kept below a threshold associated 
with a high probability of inducing sensory neuropathy. 
Additional mechanistic studies will be required to facilitate 
additional progress in the integration of PS-341 in cancer 
therapeutics.
Clinical experience in melanoma
A phase I study of PS-341 and INFα-2b in patients 
with metastatic melanoma with the primary objective 
of determining the safety, tolerability and dose limiting 
toxicities of the combination therapy showed that PS-341 and 
IFN can be safely administered in patients with treated CNS 
metastasis. Toxicities were similar to IFN alone. Antitumor 
response to slowly proliferating tumors are limited. Accrual 
continues to the highest dose level.52
A phase I trial of DTIC and PS-341 in melanoma and soft 
tissue sarcoma showed that the recommended phase II doses 
will be at least DTIC 250 mg/m2 and PS-341 1.6 mg/m2, and 
dose escalation continues. Treatment has been generally well 
tolerated with known DTIC and PS-341 toxicities. Among 
eight melanoma patients, there is one partial PR, one with 
SD on treatment for 15 weeks, six with progressive disease at 
6, 7, 8, 8, 13, and 13 weeks, respectively. At full dose PS-341 
and moderate dose DTIC for this schedule, this regimen was 
feasible and generally well-tolerated. Activity beyond that of 
DTIC alone is not apparent to date, but several or all patients 
have been treated at less than maximum tolerated doses.53
In a phase II study of PS-341 in the treatment of metastatic 
malignant melanoma, PS-341 was administered at 1.5 mg/m2 
intravenous bolus twice weekly for two weeks out of every 
three weeks. Twenty-six patients were evaluable for toxicity, 
of which 10 patients (42%) had grade 3 toxicities. This study 
demonstrated that single agent PS-341 is ineffective and toxic 
in metastatic melanoma patients at the dose and schedule 
used in this trial.51
MEK inhibitors
Mechanism of action
MEK is a tyrosine kinase downstream of B-Raf in the MAPK 
pathway. In the aberrant activation of MAPK pathway, 
a mitogen signal transduction pathway provides proliferative 
advantage to tumor cells. The binding of growth factors 
induces receptor dimerization and autophosphorylation on 
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tyrosine residues. This exchange elicits a conformational 
change in Ras, a membrane localized protein. This change 
enables it to bind to Raf-1 and recruit it from the cytosol 
to the cell membrane, where Raf-1 activation takes place. 
Activated Raf-1 phosphorylates and activates MEK, which 
in turn phosphorylates and activates extracellular signal-
regulated kinase (ERK). Activated ERK has many substrates 
in the cytosol (eg, cytoskeletal proteins, phospholipase A
2
, 
and signaling proteins, including tyrosine kinase recep-
tors, estrogen receptors, SOS, STAT proteins, and others). 
ERK can enter the nucleus to control gene expression by 
phosphorylating transcription factors, leading to overpro-
duction of components involved in angiogenesis and tumor 
progression.54
As the melanomas progress, there is functional redundancy 
between the numerous signaling pathways. It was shown 
that targeting either the PI3K or MEK pathway alone led 
to cytostasis and was associated with a reversible G1-phase 
cell cycle arrest.55,56 The MEK inhibitor AZD6244 led to the 
stabilization of established human melanoma xenografts, but 
not tumor regression,55 suggesting that the effects of MEK 
inhibition in this setting were largely cytostatic. Lack of good 
cytotoxic activity after either MEK or PI3K inhibition alone 
suggests that multiple signaling pathways need to be targeted 
simultaneously to induce melanoma regression.
The current expectation is that BRAF inhibitors will 
be used in combination with either other targeted therapy 
agents or established chemotherapy regimens. However, it is 
necessary to rigorously evaluate each of the novel BRAF 
and MEK inhibitors as single agents so that we understand 
their distinct pharmacological properties and their respective 
abilities to hit their target and perturb proliferation or cell 
viability. Only with this knowledge can we make an informed 
selection of agents for further development.
Safety profile
The safety profile of MEK inhibitors has not been optimal as 
dose-limiting diarrhea and rash possibly preclude the delivery 
of a dose required to adequately suppress the MAPK pathway. 
Phase II trials of this drug were suspended because of the 
occurrence of retinal vein thrombosis in several patients.
Clinical experience in melanoma
The MEK inhibitors – PD0325901 and AZD6244 – have 
progressed through phase I, and in the case of AZD6244, 
phase II clinical trials. PD0325901 has been evaluated in a 
phase I trial, in which most of the patients had melanoma. 
Of these patients, two out of 27 experienced an objective 
response (OR) and five additional patients showed some 
SD. AZD6244 was evaluated in a phase I trial among 
patients with advanced solid tumors.57 Of the melanoma 
patients treated, none had an OR; however, four patients 
maintained SD for more than six months, suggesting a 
clinical benefit.
A randomized phase II trial was completed among 
200 patients with melanoma. Patients were randomized in 
a 1:1 manner to AZD6244 or temozolomide.58 Five ORs 
were observed among 42 patients with BRAF V600E muta-
tions (12% OR rate), indicating that a subset of BRAF 
mutant melanomas may be sensitive to this agent. As there 
was no improvement in PFS compared with single-agent 
temozolomide, AZD6244 was deemed insufficient to warrant 
further single-agent clinical trials in melanoma.
As the preclinical data support the selective activity 
of RAF and MEK inhibitors in BRAF mutant melanoma, 
stratifying the correct patient population for clinical trials is 
imperative for designing effective and informative clinical 
trials. This also requires real-time mutation screening as part 
of the clinical trial. If a responsive subset of BRAF-mutated 
melanomas can be identified, it may be possible to rapidly 
develop RAF and MEK inhibitors as single agents for 
this population, whereas combination strategies would be 
explored for the remaining.
Thalidomide
Mechanism of action
On May 26, 2006, the FDA granted accelerated approval 
for thalidomide in combination with dexamethasone 
for the treatment of newly diagnosed multiple myeloma 
patients. Thalidomide was introduced in the late 1950s as 
a sedative and for the treatment of morning sickness in 
pregnant women. The drug was withdrawn from the market 
in the early 1960s because reports of birth defects such as 
phocomelia were associated with its use. Thirty years later, 
it was established that this complication was secondary to 
inhibition of blood vessel growth in the development of 
fetal limb buds. However, thalidomide and its analogues 
(lenalidomide, CC-4047) have immunomodulatory, 
antiangiogenic, antiproliferative, and proapoptotic 
properties, which are responsible for antitumor action. 
Thalidomide also inhibits the inflammatory response by 
decreasing cyclooxygenase-2 activity.59,60 Thalidomide is 
a potent inhibitor of TNF-α by inducing TNF-α mRNA 
degradation,61 and thereby decreasing the density of 
TNF-α-induced adhesion molecules such as ICAM-I and 
VCAM-I.62 Thalidomide and its analogues reduce the 
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expression of proangiogenic factors such as VEGF and thus 
prevent angiogenesis.63 Thalidomide also causes induction 
of NK cells and increase the levels of IL-2, IL-2 receptors, 
and IFN-γ, leading to tumor cell lysis and modulate the 
immune system to induce anticancer activity.64 The function 
of other cytokines, such as IL-6 and IL-12, are inhibited 
by thalidomide, along with its effect on the expression of 
cell adhesion molecules.65–67 Mechanisms of thalidomide-
induced apoptosis include cell growth arrest at the G1 
phase, downregulation of NFκB and apoptosis inhibitory 
protein (AIP), and activation of caspase 8.68
Safety profile
Thalidomide as a single agent in a daily dose up to 400 mg 
was well tolerated. The main toxicities are dose-dependent 
neuropathy, constipation, anorexia, dry mouth, skin rash, 
and fatigue. Most of the toxicities were manageable and 
reversible.
Clinical experience in melanoma
In a phase II efficacy study of a regimen including TMZ, 
thalidomide, and whole brain radiation therapy (WBRT) 
in patients with brain (central nervous system [CNS]) 
metastases from melanoma, 39 patients received treatment 
and seven patients had stable CNS disease at 10 weeks. 
No patient exhibited a systemic response. Median time to 
progression was seven weeks and median OS was four months. 
Grade 3–4 side effects included deep venous thrombosis (3), 
pulmonary embolism (1), and CNS events (12). Eighteen 
(45%) patients required admission for side effects (7) and/or 
symptomatic disease progression (11). The efficacy of TMZ, 
thalidomide, and WBRT in the treatment of CNS metastatic 
melanoma is low.69
A phase II study evaluated the efficacy and tolerability 
of DTIC in combination with thalidomide in metastatic 
melanoma patients. Fifteen patients were enrolled in the 
study. Of the 13 patients evaluable for response, one patient 
had a PR, three patients had SD, and nine patients had PD. 
No complete responses were seen. Grade III neutropenia, 
thrombocytopenia and nausea were attributed to DTIC. 
Grade III/IV constipation, peripheral neuropathy, fatigue, 
edema and rash were attributed to thalidomide. The addi-
tion of thalidomide to DTIC in metastatic melanoma 
yielded activity insufficient to proceed with additional 
trials of this combination. Thalidomide dose escalation 
beyond 200 mg/day was limited by unacceptable toxicity. 
Therefore, this combination does not warrant further 
investigation.70
Phase II studies evaluating single-agent thalidomide 
in metastatic malignant melanoma, showed no objective 
response, but few cases of stable disease. Among 36 eligible 
patients, 35 were evaluable for response. SD is very rare in 
patients with brain metastases with or without any treatment. 
Four patients (11%) had stable brain metastases for more 
than four months on thalidomide, providing some indica-
tion of thalidomide activity in the CNS. The responding 
patient in the study progressed during treatment, with 
concomitant disease control in peripheral manifestations. 
This demonstrates thalidomide’s activity in peripheral tumor 
manifestations.71
In a phase II trial evaluating efficacy of pegylated INF 
and thalidomide in melanoma, pegylated INF was admin-
istered at a dose of 0.5 µg/kg subcutaneously weekly and 
thalidomide 200 mg orally daily. Eighteen patients were 
enrolled in this trial. Severe (grade 4) toxicities observed 
were anemia in two patients and thrombocytopenia in one 
patient. No ORs were noted. Three patients demonstrated 
SD. The regimen of pegylated INF and thalidomide was 
well tolerated. The combination, however, failed to demon-
strate clinical efficacy in pretreated metastatic malignant 
melanoma.72
Conclusion
Melanoma continues to be a cancer that is exquisitely 
resistant to treatment. Chemotherapy and immunotherapy 
have thus far failed to make an impact on survival in the 
metastatic setting while immunotherapy leads to a modest 
improvement in survival in the adjuvant setting. Elucidation 
of the molecular mechanisms of carcinogenesis in melanoma 
have expanded the horizon of opportunity to alter the natural 
history of the disease. Multiple signal transduction pathways 
seem to be aberrant and drugs that target them have been 
and continue to be in development. In this review we have 
presented data on the most promising agents in develop-
ment. However, it is important to note that all of these agents 
have been used singly or occasionally in combination with 
chemotherapy. It has become quite apparent that the inhibi-
tion of one pathway can lead to the upregulation of other 
related or redundant pathways. This may negatively affect 
its activity or likely lead to resistance therefore combina-
tion of therapies utilizing these agents seems to be the most 
promising approach in the near future. Mutational analysis 
of melanoma tissue can identify patients more likely to 
benefit from targeted agents. However, more comprehen-
sive molecular profiling will refine our ability to rationally 
individualize the treatment of melanoma.
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